Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy
ConclusionsProgression-free survival may be enhanced by the use of targeted therapy with concurrent radiotherapy, use of multimodal therapy, and use of newer targeted therapy. Future clinical trials should consider use of concurrent radiotherapy and multimodal therapy for patients with advanced chordoma. (Source: Targeted Oncology)
Source: Targeted Oncology - April 24, 2021 Category: Cancer & Oncology Source Type: research
The Activity of Crizotinib in Chemo-Refractory MET -Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcS é-Crizotinib Program
ConclusionsLarge-scale screening forMET-amplified esogastric adenocarcinomas is feasible.MET amplification was observed in 5.5% of gastric and 12.8% of esophageal adenocarcinomas. Crizotinib shows encouraging results in selected patients. Thus, c-MET inhibition forMET-amplified tumors deserves further evaluation.Trial Registration NumberNCT02034981.Date of Registration14 January 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2021 Category: Cancer & Oncology Source Type: research
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
ConclusionsBintrafusp alfa demonstrated a manageable safety profile and efficacy in Asian patients with pretreated esophageal SCC.Clinical Trials RegistrationNCT02699515. (Source: Targeted Oncology)
Source: Targeted Oncology - April 11, 2021 Category: Cancer & Oncology Source Type: research
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
ConclusionsThese real-world data complement the findings from randomized controlled trials, indicating that first- and second-line AAP is well tolerated and effective in patients with mCRPC, including those with underlying CV comorbidities.Trial Registration NumberNCT02236637, registered 8 September 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - April 7, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
A correction to this paper has been published: https://doi.org/10.1007/s11523-021-00812-7 (Source: Targeted Oncology)
Source: Targeted Oncology - March 31, 2021 Category: Cancer & Oncology Source Type: research
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
AbstractLiquid biopsy recently gained widespread attention as a noninvasive alternative/complementary technique to tissue biopsy in patients with cancer. As technological advances have improved both feasibility and turnaround time, liquid biopsy has expanded tumor molecular analysis with acknowledgement of both spatial and temporal heterogeneity, overcoming many limitations of traditional tissue biopsy. Because of its diagnostic, prognostic, and predictive value, liquid biopsy has been extensively studied also in metastatic colorectal cancer. Indeed, as personalized medicine establishes its role in cancer treatment, geneti...
Source: Targeted Oncology - March 18, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Sequential Treatment of Sorafenib –Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
A correction to this paper has been published: https://doi.org/10.1007/s11523-021-00808-3 (Source: Targeted Oncology)
Source: Targeted Oncology - March 18, 2021 Category: Cancer & Oncology Source Type: research
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
AbstractLoss-of-function mutations inBRCA1 andBRCA2 are detected in at least 5% of unselected patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for DNA homologous recombination repair (HRR). This review provides an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of BC. Olaparib and talazoparib are PARP inhibitors approved as monotherapies for deleterious/suspected deleterious germline BRCA-mutated, HER2-negative BC. Olaparib is approved in the USA for metastatic BC and in Europe for locally advanced/metastatic BC. Talazoparib is approved for locally adva...
Source: Targeted Oncology - March 12, 2021 Category: Cancer & Oncology Source Type: research
Coming of Age of Immunotherapy of Urothelial Cancer
AbstractFollowing platinum-based regimens becoming the reference standard of care, it has taken almost four decades to find a systemic treatment that improved overall survival in metastatic urothelial tumors. Single-agent immune checkpoint inhibitors have not only improved overall survival but also the quality of life of patients with metastatic urothelial tumors after failure of platinum-based regimens and as a maintenance therapy after four to six cycles of standard first-line chemotherapy. In addition, very promising data are emerging when single-agent immunotherapy is offered as adjuvant or neoadjuvant treatment for pa...
Source: Targeted Oncology - March 12, 2021 Category: Cancer & Oncology Source Type: research
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer
ConclusionsOur findings suggest that177Lu-PSMA radioligand therapy provides a significant response rate with a low toxicity profile. The evidence promotes greater efficacy of radioligand therapy in predominantly lymph node metastatic castration-resistant prostate cancer, and in individuals with chemotherapy-na ïve status and lower levels of baseline PSA. (Source: Targeted Oncology)
Source: Targeted Oncology - March 9, 2021 Category: Cancer & Oncology Source Type: research
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
AbstractDysregulation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin signaling is common in both indolent and aggressive forms of malignant lymphoma, for which several targeted therapies have been developed. Copanlisib is a highly selective and potent intravenous pan-class I PI3K inhibitor that has demonstrated durable objective responses and a manageable safety profile in heavily pre-treated patients with indolent lymphomas. As a result, copanlisib monotherapy received accelerated approval from the US Food and Drug Administration for the treatment of adults with relapsed follicular ...
Source: Targeted Oncology - March 9, 2021 Category: Cancer & Oncology Source Type: research
Sequential Treatment of Sorafenib –Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis
ConclusionThis study provides additional proof of the superiority of the S –R treatment over the S–P treatment approach in advanced HCC patients from a real-life setting. (Source: Targeted Oncology)
Source: Targeted Oncology - March 1, 2021 Category: Cancer & Oncology Source Type: research
Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison
ConclusionsThe present MAIC highlights that the combination of atezolizumab plus bevacizumab is superior to lenvatinib. However, updated data or sub-analyses of the IMbrave150 trial would provide more robust estimates for such a treatment comparison. (Source: Targeted Oncology)
Source: Targeted Oncology - February 27, 2021 Category: Cancer & Oncology Source Type: research
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR -Mutated NSCLC
ConclusionsPre-treatmentEGFR copy number gain determined by amplicon-based next generation sequencing data predicts worse overall survival inEGFR-mutated patients treated with first-line EGFR-tyrosine kinase inhibitors. T790M at relapse and subsequent treatment with osimertinib predict longer overall survival. (Source: Targeted Oncology)
Source: Targeted Oncology - February 19, 2021 Category: Cancer & Oncology Source Type: research
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
ConclusionLS BRAFmt cancers share many features with RS BRAFmt cancers, including poor survival outcomes. Mature data on the activity of BRAF-targeted therapies in the first-line setting are eagerly awaited. (Source: Targeted Oncology)
Source: Targeted Oncology - February 18, 2021 Category: Cancer & Oncology Source Type: research
